Physician profile
Mikaela Marie Olsen
NPI 1285233502
$130,254.57
in general payments reported to CMS, 2019-2025
33 companies · $52K in 2025
The $52K reported for 2025 was more than what 99% of Oncology (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $263).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $323 · 2022: $3,997 · 2023: $32K · 2024: $42K · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $48K · Consulting Fee: $25K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Honoraria: $9,370 · Food and Beverage: $8,981 · Education: $5,820 · Grant: $3,500 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $48,473.81 |
| Consulting Fee | $24,730.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,757.43 |
| Honoraria | $9,370.00 |
| Food and Beverage | $8,981.36 |
| Education | $5,819.96 |
| Grant | $3,500.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,301.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $98,494.16 | 2022-2025 | Bd Phaseal, Alaris, Smartsite, Texium |
| Biolife, L.L.C. | $17,315.26 | 2023-2025 | |
| Bard Peripheral Vascular, INC. | $2,360.72 | 2023-2024 | Powerport M.R.I. Implantable Port |
| Koru Medical Systems, INC. | $1,750.00 | 2025 | F10020- Freedom Edge |
| Astrazeneca Pharmaceuticals Lp | $1,247.83 | 2023-2025 | Calquence |
| Daiichi Sankyo INC. | $1,119.75 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Janssen Biotech, INC. | $922.18 | 2021-2025 | Tecvayli, Carvykti, Rybrevant |
| Genmab U.S., INC. | $775.30 | 2023-2025 | Epkinly |
| Genentech USA, INC. | $633.24 | 2022-2024 | Venclexta, Gazyva, Gavreto |
| E.R. Squibb & Sons, L.L.C. | $591.67 | 2023-2025 | Opdivo, Reblozyl |
| Incyte Corporation | $515.36 | 2021-2025 | |
| Taiho Oncology, INC. | $488.50 | 2023-2025 | |
| Amgen INC. | $485.29 | 2021-2025 | Imdelltra (Amg757), Lumakras |
| Seagen INC. | $440.01 | 2021-2023 | Adcetris, Padcev |
| Stemline Therapeutics INC. | $273.71 | 2024 | Orserdu |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $270.90 | 2024-2025 | Reblozyl, Opdivo |
| Btg International INC. | $268.07 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $231.79 | 2023-2024 | Tazverik, Onivyde, Somatuline Depot |
| Takeda Pharmaceuticals U.S.A., INC. | $221.21 | 2023-2025 | Iclusig |
| Bayer Healthcare Pharmaceuticals INC. | $212.21 | 2021-2025 | |
| Fennec Pharmaceuticals, INC. | $211.97 | 2025 | Fyarro |
| Abbvie INC. | $210.04 | 2024 | |
| Genzyme Corporation | $206.64 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $198.72 | 2023-2025 | Libtayo |
| Lilly USA, LLC | $178.29 | 2024 | Retevmo, Jaypirca, Verzenio |
| Legend Biotech USA INC. | $178.10 | 2024 | Carvykti |
| Sanofi-Aventis U.S. LLC | $125.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $105.03 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $66.12 | 2024-2025 | |
| Gilead Sciences, INC. | $64.90 | 2025 | Trodelvy |
| Pfizer INC. | $39.12 | 2024 | |
| Jazz Pharmaceuticals INC. | $31.77 | 2024 | |
| Geron Corporation | $21.71 | 2025 | Rytelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mikaela Olsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.